455 Mission Bay Boulevard South
San Francisco, CA 94158
United States
415 482 5300
https://www.nektar.com
Settore/i:
Settore:
Impiegati a tempo pieno: 137
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Mr. Howard W. Robin | CEO, President & Director | 2,21M | N/D | 1953 |
Ms. Sandra A. Gardiner | Interim Chief Financial Officer | 376,3k | N/D | 1966 |
Mr. Mark A. Wilson | Senior VP, Chief Legal Officer & Secretary | 868,68k | N/D | 1972 |
Dr. Jonathan Zalevsky Ph.D. | Chief Research & Development Officer | 1,6M | N/D | 1975 |
Vivian Wu | Director of Investor Relations & Corporate Affairs | N/D | N/D | N/D |
Mr. Robert Bacci | Senior Vice President of Human Resources & Facilities Operations | N/D | N/D | N/D |
Ms. Jennifer Ruddock | Chief Business Officer | N/D | N/D | N/D |
Dr. Mary Tagliaferri L.Ac., M.D. | Chief Medical Officer | N/D | N/D | 1966 |
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.
L'ISS Governance QualityScore di Nektar Therapeutics al 1 maggio 2024 è 6. I criteri di valutazione fondamentali sono revisione: 8; Consiglio di Amministrazione: 7; diritti degli azionisti: 2; retribuzione: 8.